3. The Company Woman

The name Latham Pryor led Hale to a dead end before lunch.

He spent the morning at the Port Gantry Public Library again, searching through business directories, professional registries, and back issues of the Meridian City Commercial Register. The name appeared nowhere. No Latham Pryor was listed in any pharmaceutical directory, any corporate registry, any professional association. The man who had visited Edith Morrow and Walter Kemp, who had asked questions about their pain and smiled while they signed papers they could not read, was a ghost.

Hale sat at the microfiche reader until his eyes burned, and when the library closed for the noon hour, he walked to a diner on Cordova Street and ordered coffee he could not afford and eggs he did not eat. The blister packs were in his coat pocket, a faint rattle every time he moved. Two dead people in two nights, and he had their medication in his pocket like a talisman.

The waitress refilled his coffee without asking. She was a woman in her fifties with bleached hair and a name tag that read DOT. The diner was empty except for a man in a work jacket reading a newspaper at the counter and a young couple arguing quietly in a booth by the window. The radio behind the counter played a song about heartbreak in a town Hale had never visited.

He pulled out his notebook and reviewed what he knew. The pattern at Silver Pines was clear: elderly patients were recruited into an Exaltrex study, their dosages were increased rapidly, and they died within six to eight weeks of cardiac events that were written off as natural causes. The attending physician, Dr. Leland Orvis, signed death certificates without examining the bodies. The drug manufacturer, Ravenwood Pharmaceuticals, reported no adverse events to the FDOA. The recruiter, Latham Pryor, did not exist in any public record.

It was a machine designed to produce corpses. And every part of the machine was legal.

The door of the diner opened, letting in a gust of cold air and a woman in a dark blue coat. She was tall, with brown hair pulled back in a neat twist, and she carried a leather briefcase that looked expensive. She scanned the room with the kind of efficient attention that Hale recognized from his years in investigations: the look of someone who was always cataloging exits and potential threats. Her eyes paused on him for a fraction of a second longer than necessary, then moved on.

She took a seat at the counter, two stools away from the man in the work jacket, and ordered tea. Her voice was low and precise. She did not look at Hale again.

Hale returned to his notebook, but some part of his attention stayed fixed on the woman. There was something about the way she sat, the way she held herself apart from the room, that did not belong in a diner on Cordova Street. She was dressed for a boardroom, not a Port Gantry greasy spoon.

The waitress brought her tea, and the woman wrapped her hands around the cup as if she were warming them after a long cold walk. She still did not look at Hale.

"You're the one who found Edith Morrow," she said.

Her voice carried across the empty space between them without rising. It was a statement, not a question. Hale felt his spine tighten.

"Who's asking?"

The woman turned on her stool to face him. Her eyes were gray, the color of winter water, and her face was composed in an expression that revealed nothing. "My name is Marlene Draper. I'm the regional medical director for Ravenwood Pharmaceuticals. I was notified this morning that Silver Pines had two deaths in two nights. Both patients in our compassionate use program. I came to review the files and ensure protocol compliance." She paused. "The night orderly finding both bodies seems like more than coincidence. I wanted to meet you."

Hale studied her face, looking for the tells that had been his trade for fifteen years: micro-expressions, eye movements, the small betrayals of the body that signaled deception. He found nothing. Marlene Draper had the kind of composure that was either genuine or very expensive to maintain.

"Compassionate use program," Hale said. "Is that what you call it?"

"That's what the FDOA calls it. We're providing Exaltrex to chronic pain patients who might otherwise have no treatment options. Silver Pines is one of twelve facilities in the region participating." She lifted her teacup and took a sip without breaking eye contact. "You have concerns."

"I have questions."

"Then ask them."

Hale closed his notebook. The diner suddenly felt very small, the radio music very far away. "Mrs. Morrow's pupils were constricted when I found her. Pinpoint. Walter Kemp was vomiting blood and his heart was racing before he collapsed. Both of them were on Exaltrex. Both of them died within six weeks of starting the drug. That's not compassionate use. That's a pattern."

Marlene Draper set down her teacup. Her expression did not change, but something shifted behind her eyes, a flicker that might have been surprise or might have been the recognition of a problem she had not anticipated.

"How do you know about the six-week pattern?" she asked.

"I can read death certificates."

"Those are confidential medical records."

"I work there. I have access." Hale leaned forward, his elbows on the counter. "Mrs. Morrow told me a man in a suit recruited her into the program. She signed papers she couldn't read. Walter Kemp told me the same thing. They both thought they were helping people. They both died with their eyes frozen open. Tell me that's protocol."

The man in the work jacket folded his newspaper and left, his coffee cup still half full. The young couple had stopped arguing and were watching Marlene Draper with the idle curiosity of people who sensed drama and wanted to see how it unfolded. Dot the waitress was polishing glasses behind the counter, pretending not to listen.

Marlene Draper was quiet for a long moment. Then she said, "Not here."

She stood, leaving her tea unfinished, and walked toward the door. Her heels clicked on the linoleum in a rhythm that sounded like a countdown. At the door, she turned and looked at Hale.

"There's a chapel at Silver Pines," she said. "The old one, behind the east wing. It's not used anymore. Meet me there at four o'clock."

Then she was gone, the door swinging shut behind her, the cold air rushing in to fill the space she had left.

Hale sat at the counter for a long time after she left, his coffee growing cold in its cup. Dot came over and refilled it anyway.

"Friend of yours?" Dot asked.

"I don't know what she is," Hale said.

The chapel at Silver Pines was a relic from the facility's original construction, a small room at the end of a corridor that no longer served any purpose except storage. The pews had been pushed against the walls and stacked with boxes of medical supplies. The altar was covered in a dust cloth. The stained glass window behind it depicted a shepherd carrying a lamb, but the glass was cracked in two places and the afternoon light came through in fractured colors.

Marlene Draper was already there when Hale arrived. She had changed out of her dark blue coat into a gray sweater that made her look younger and less formidable. She was standing in front of the stained glass window, her back to the door, her arms crossed over her chest.

"I used to believe in things," she said without turning around. "When I was young. I used to believe that medicine was a sacred trust. That the companies I worked for existed to heal people." She turned to face him. "I don't believe that anymore."

Hale closed the door behind him. The chapel smelled of dust and old incense and the faint chemical tang of the supplies in their boxes. "What do you believe?"

"I believe that my company is doing something terrible, and I don't know how to stop it."

The words hung in the air between them. Hale had expected denial, deflection, the kind of corporate evasiveness that he had encountered a hundred times in his investigations. He had not expected this.

"Why are you telling me?"

"Because you're the first person who's noticed." Marlene walked to one of the pews and sat down heavily, as if the confession had drained something out of her. "The deaths at Silver Pines aren't the first. There have been others, at other facilities. But they're all classified as natural causes, and the FDOA receives no adverse event reports, and the program continues because the program is technically legal."

"Technically legal," Hale repeated.

"The Exaltrex compassionate use program is structured as a Phase IV observational study. That's a specific regulatory category. It means we're monitoring a drug that's already been approved, in a real-world setting, to gather additional data on safety and efficacy. Under FDOA guidelines, observational studies don't require the same informed consent protocols as clinical trials. They don't require the same adverse event reporting. Patients are told they're helping advance science, and they are, but they're not told that the dosage they're receiving is higher than what's recommended on the label."

"How much higher?"

Marlene met his eyes. "The approved maintenance dose for Exaltrex is twenty milligrams. The compassionate use protocol calls for forty milligrams for all patients over seventy. The company's position is that elderly patients metabolize the drug more slowly and require a higher dose to achieve therapeutic effect. But the internal data shows that at forty milligrams, Exaltrex causes a cardiac arrhythmia called torsades de pointes in approximately fifteen percent of patients. That's a fatal rhythm if not treated immediately. In a nursing home, at night, with no cardiac monitoring, it's a death sentence."

Hale felt the cold anger settling into his chest, familiar and welcome. "Why are you telling me this? You work for them."

"My father died three years ago." Marlene's voice was steady, but her hands were gripping the edge of the pew. "He had Parkinson's. He was in a facility in Meridian City, one of the first ones to participate in the Exaltrex program. The recruiter told him he was contributing to research that would help millions of people. He was so proud. Two months later, he was dead. Congestive heart failure, according to the death certificate. I didn't question it at the time. I was working for Ravenwood, in the marketing department then, and I believed the company line."

"When did you stop believing?"

"When I was promoted to regional medical director and got access to the safety data. I found my father's file in the database. He wasn't an isolated case. He was part of a cluster. Eight deaths in his facility alone, all within the same time window, all on the same dosage." She looked away, at the cracked shepherd in the window. "I could have gone to the FDOA then. I could have blown the whistle. But I didn't. I took the promotion instead, and I told myself I was gathering evidence from the inside."

"Are you?"

"I have documents. Internal memos. Dosage protocols signed by the vice president of clinical development. Safety reports that were never filed with the FDOA." She reached into her bag and pulled out a manila envelope, thick with paper. "This is everything I've collected over the past eighteen months. It's not enough to convict anyone, but it's enough to start asking questions."

Hale took the envelope. It was heavy, heavier than paper should be. "What's the catch?"

"The catch is that I'm a coward." Marlene smiled, a thin expression that did not reach her eyes. "I don't want to go to prison for stealing company documents. I don't want to be blackballed from the industry. I want someone else to take the risk. Someone who has nothing left to lose."

"You've been watching me."

"I've been watching Silver Pines. You happened to be there." She stood up, smoothing her sweater. "There's a compliance review scheduled for the facility next week. I'll be leading it. If you can find evidence that connects the deaths directly to the Exaltrex protocol—not just correlation, but causation—I can include it in my report and force the company to suspend the program pending a formal investigation. But I need something concrete. Something that can't be explained away."

"What about Dr. Orvis? He's signing the death certificates."

"Orvis is a contractor. He's paid per signature. He's not part of the conspiracy; he's just indifferent. Going after him won't stop anything." She walked toward the door, then paused with her hand on the knob. "The man in the suit is Latham Pryor. He's not a physician. He's a patient recruiter, employed by a contractor that Ravenwood uses to insulate itself from liability. He doesn't exist in the corporate directory because he's not technically a Ravenwood employee. I can't access his files without triggering an internal investigation."

"Then how do I find him?"

Marlene turned to look at him one last time. "He visits Silver Pines every other Tuesday. The next visit is in three days. He'll be there to recruit new patients for the program." She opened the door, letting in the cold air from the corridor. "Be careful, Mr. Hale. The people who designed this program are not stupid. They've built a machine that operates entirely within the law. The only way to stop it is to prove that the law is wrong, and that's a fight that most people lose."

She left him in the chapel with the envelope in his hands and the dust of decades settling on his shoulders.

Hale sat alone in the dim light, the fractured colors from the stained glass window painting his hands in shades of red and blue. He opened the envelope and began to read.

The documents were dense, the language dense with medical terminology that he only half understood. But the pattern was unmistakable. Internal memos from something called the Clinical Development Oversight Committee, signed by a name he recognized from the press release: Marcus Draven, Vice President of Clinical Development. The memos discussed the Exaltrex compassionate use program in terms that were chilling in their precision: target enrollment, projected mortality, acceptable adverse event thresholds.

One memo, dated eighteen months earlier, caught his attention. It was a risk assessment for the Phase IV study, and it contained a paragraph that Hale read three times:

"Given the elevated cardiac risk profile at the forty-milligram dosage, the study should be structured to minimize external scrutiny of mortality data. Facilities in rural or underserved areas are preferred, as local medical examiners are less likely to conduct autopsies in the absence of family requests. Death certificates should list underlying conditions as primary cause of death, with the study drug noted only as a concomitant medication. Under current FDOA guidelines, this approach is fully compliant with Phase IV reporting requirements."

Fully compliant. The words sat on the page like a dare. The memo was not a confession of murder. It was a business plan that accounted for a certain number of deaths as an acceptable cost. The genius of it was that it did not hide the deaths; it simply classified them in a way that made them invisible to regulators.

Hale closed the envelope. The chapel was growing dark as the afternoon light faded. Outside, the pine trees were beginning their evening scrape against the roof, and somewhere in the west wing, the evening shift was arriving, the day nurses were leaving, and the machinery of Silver Pines was turning over for another night.

He put the envelope inside his coat and walked out into the corridor. At the end of the hall, the lights of the nurses' station were on, and he could hear the radio playing something soft and forgettable. Gretchen Foss was at the desk, writing in the logbook. She did not look up when he passed.

Hale walked to room fourteen, where Walter Kemp's body had been removed and the floor had been cleaned and the bed had been stripped. In the morning, a new patient would arrive. In a few weeks, Latham Pryor would visit in his nice suit and ask the new patient about their pain. And six weeks after that, the cycle would complete itself again.

He pulled out his notebook and wrote one more entry:

Marlene Draper. Ravenwood. Phase IV observational study. 40mg dosage = 15% cardiac arrhythmia. Memo admits known risk, classifies deaths as underlying conditions. Latham Pryor visits Tuesday.

Then he added, in smaller letters at the bottom of the page:

She says her father died in the program. Check if it's true.

Because Dominic Hale had not survived fifteen years as an investigator by trusting people who confessed too easily. Marlene Draper had given him everything he needed, wrapped in a story about a dead father and a guilty conscience. It was a good story. It was exactly the kind of story that a smart woman would tell a desperate man to make him feel like an ally instead of a tool.

He wanted to believe her. That was the dangerous part.

He folded the notebook and walked out into the evening, the envelope heavy against his ribs, the blister packs still rattling in his pocket. In three days, Latham Pryor would come to Silver Pines. Hale intended to be there, and he intended to get answers.

But first, he needed to find out whether Marlene Draper was telling the truth. And there was only one person in the world who could help him do that.